Promising drug for rare skin disease falls short in early trial
NCT ID NCT05979831
First seen May 25, 2026 · Last updated May 25, 2026
Summary
This study tested a new drug called DS-2325a in 9 adults with Netherton Syndrome, a rare genetic condition causing severe skin redness, scaling, and barrier problems. The trial aimed to check safety and early signs of effectiveness, but it was terminated early. The main focus was on side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Saint Louis Hospital
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.